5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and angiotensin ii

5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide has been researched along with angiotensin ii in 2 studies

Compound Research Comparison

Studies (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide)	Trials (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide)	Recent Studies (post-2010) (5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide)	Studies (angiotensin ii)	Trials (angiotensin ii)	Recent Studies (post-2010) (angiotensin ii)
73	0	8	38,152	1,089	7,413

Protein Interaction Comparison

Protein	Taxonomy	angiotensin ii (IC50)
Atrial natriuretic peptide receptor 3	Homo sapiens (human)	0.002
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	0.002
Type-1B angiotensin II receptor	Rattus norvegicus (Norway rat)	0.0018
Type-1 angiotensin II receptor	Homo sapiens (human)	0.0055
Type-2 angiotensin II receptor	Rattus norvegicus (Norway rat)	0.004
Type-2 angiotensin II receptor	Homo sapiens (human)	0.0011

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Belloni, AS; Cavallin, M; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Rossi, GP; Sartore, S	1
Belloni, AS; Kreutz, R; Nussdorfer, GG; Paul, M; Pessina, AC; Rossi, GP; Seccia, TM	1

Other Studies

2 other study(ies) available for 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and angiotensin ii

Article	Year
Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension. Cardiovascular research, 2002, Volume: 55, Issue:1 Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; Aorta; Biphenyl Compounds; Bosentan; Calcium Channel Blockers; Collagen; Dansyl Compounds; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Immunohistochemistry; Irbesartan; Male; Muscle, Smooth, Vascular; Nifedipine; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles	2002
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4 Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Biphenyl Compounds; Bosentan; Cardiomyopathies; Dansyl Compounds; Disease Models, Animal; Endothelin-1; Fibrosis; Hypertension; Irbesartan; Male; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cell Surface; Sulfonamides; Tetrazoles; Time Factors; Vasoconstrictor Agents	2003

Article

Year

Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.

Cardiovascular research, 2002, Volume: 55, Issue:1

Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; Aorta; Biphenyl Compounds; Bosentan; Calcium Channel Blockers; Collagen; Dansyl Compounds; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Immunohistochemistry; Irbesartan; Male; Muscle, Smooth, Vascular; Nifedipine; Rats; Rats, Sprague-Dawley; Sulfonamides; Tetrazoles

2002

Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.

Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4

Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Biphenyl Compounds; Bosentan; Cardiomyopathies; Dansyl Compounds; Disease Models, Animal; Endothelin-1; Fibrosis; Hypertension; Irbesartan; Male; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cell Surface; Sulfonamides; Tetrazoles; Time Factors; Vasoconstrictor Agents

2003